Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corp (BBLG) pioneers regenerative bone repair solutions using its UCLA-licensed ucb-1™ platform. This page aggregates all official news and press releases, offering stakeholders a centralized hub for tracking advancements in orthobiologics and surgical innovation.
Access real-time updates on clinical trial milestones, regulatory submissions, and strategic partnerships that define BBLG's role in advancing bone regeneration. Our curated feed ensures investors stay informed about material developments impacting the company's trajectory in biotechnology.
Key coverage areas include progress in spinal surgery therapeutics, orthopedic procedure innovations, and collaborative research with leading medical institutions. Each update is vetted for accuracy, providing reliable insights into product pipelines and intellectual property achievements.
Bookmark this page for streamlined access to Bone Biologics' latest announcements. Enable alerts to receive immediate notifications on critical disclosures, ensuring you remain ahead in monitoring this dynamic sector.
Bone Biologics Corporation (NASDAQ: BBLG) has announced the approval of a multicenter pilot clinical trial for its NB1 bone graft by the Human Research Ethics Committee in Australia. The trial will enroll 30 adult patients undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative disc disease (DDD). This study aims to assess the safety and effectiveness of NB1, which showed promising results in animal studies. The company aims to capture a part of the $3 billion global market for spine fusion products. Furthermore, the long-term goal includes addressing osteoporosis and trauma, potentially tapping into additional markets valued at $11 billion and $8 billion, respectively.
Bone Biologics Corporation (NASDAQ: BBLG) has engaged Avania as the Contract Research Organization (CRO) for its upcoming pilot clinical trial of NB1, targeting degenerative disc disease patients undergoing Transforaminal Lumbar Interbody Fusion (TLIF). The multicenter trial will assess the safety and effectiveness of the NB1 bone graft in 30 subjects, anticipated to start in late 2023, pending ethics committee approval from the Monash Health system in Australia. The inclusion of rhNELL-1 in the NB1 device is expected to enhance bone formation. CEO Jeffrey Frelick expressed optimism about moving into human testing with Avania's support.
Bone Biologics Corporation (NASDAQ: BBLG) has announced advancements in their lead product, NB1, utilizing NELL-1 for spinal fusion treatments. The global market for bone graft substitutes is estimated at
On October 13, 2022, WallachBeth Capital LLC announced the closure of an underwritten public offering for Bone Biologics (NASDAQ: BBLG), generating total gross proceeds of $5,100,000. The offering included 3,777,778 units at $1.35 per unit, each comprised of one share of common stock and three different Series warrants. The warrants have various exercise prices and expiration timelines, with some allowing cashless exercises. Underwriters were granted a 45-day option to purchase additional securities. The offering was made under an SEC registration statement that became effective on October 6, 2022.
FAQ
What is the current stock price of Bone Biologics (BBLG)?
What is the market cap of Bone Biologics (BBLG)?
